Background
Definitions: RIF and Biochemical pregnancy
Incidence
Risk factors
Maternal age
BMI
Smoking
Stress
Pathophysiological mechanisms of recurrent implantation failure
Immunological
Natural killer cells – Peripheral and uterine
Th1/Th2 ratio and TNF-α levels
Auto-antibodies
Antiphospholipid syndrome
Hereditary thrombophilia
Infection
Altered expression of associated molecules
Hyperglycosylated hCG
Leukaemia inhibitory factor (LIF)
Other molecules
Molecule | Source | Implantation Failure, Biochemical Pregnancy, and RIF patients | Controls/healthy outcomes | Source |
---|---|---|---|---|
Hyperglycosylated hCG (levels) | Urine | 0.63 ± 1.3 mIU/ml | 5.4 ± 4.3 mIU/ml | |
Biochemical Pregnancy | Healthy Delivery | |||
(P < .0001) | (P < .0001) | |||
Prostaglandins (cPLA2a) | Endometrium | 1.001 (ratio) | 2.956 (ratio) | |
RIF patients | Controls | |||
(P < .05) | (P < .05) | |||
LIF (in secretory phase of menstrual cycle compared with proliferative phase) | Endometrium | Secretory 2162 ± 541 pg | Secretory 3489 ± 967 pg | |
Proliferative 4953 ± 1525 pg | Proliferative 4698 ± 1136 pg | |||
(P = .06) | NS | |||
RIF Patients | Controls | |||
Cellular adhesion molecules 1) αvβ3 luminal epithelium α4β1 glandular epithelium | Endometrium | HSCORE | HSCORE | |
1.1 (0.8–1.6) | 1.6 (1.1–1.9) | |||
no pregnancy | pregnancy | |||
(P = .027) | (P = .027) | |||
2.7 (2.1–3.3) | 2.3 (1.5–2.8) | |||
no pregnancy | pregnancy | |||
(P < .047) | (P < .047) |
Implantation Rate | Clinical Pregnancy Rate | Live Birth Outcome | Source | |
---|---|---|---|---|
(treatment vs. control) | (treatment vs. control) | (treatment vs. control) | ||
Tacrolimus | 45.7% vs. 0% | 64% vs. 0% | 60% vs. 0% | |
(P < 0.0001) | (P < 0.0001) | (P < 0.0001) | ||
IVIG | 34.4% vs. 13.7% | 60.2% vs. 39.3% | 49.8% vs. 31.6% | |
RR 2.708 | RR 1.475 | RR 1.616 | ||
(95% CI: 1.302–5.629, I2 = 65.0%) | (95% CI: 1.191–1.825, I2 = 65.7%) | (95% CI: 1.243–2.101, I2 = 58.2%) | ||
PBMC | 22% vs. 4.88% | 39.58% vs. 14.29% | 33.33% vs.9.58% | |
(P = 0.014) | (P = 0.038) | (P = 0.038) | ||
G-CSF | 31.5% vs. 13.9% | 48.1% vs. 25% | 33.3% vs. 17.3% | |
(P < 0.01) | (P < 0.01) | NS | ||
Antibiotics for CE | 37% vs. 17% | 65.2% vs. 33% | 60.8% vs. 13.3% | |
NS | (P = 0.039) | (P = 0.02) | ||
Salpingectomy | 25.6% vs. 12.3% | 45.7% vs. 22.5% | 40% vs. 17.5% | |
(P = 0.038) | (P = 0.029) | (P = 0.038) | ||
Endometrial Biopsy | 27.7%, vs. 14.2% | 66.7% vs. 30.3% | 48.9% vs. 22.5% | |
(P = .00011) | (P = .00009) | (P = .016) | ||
IMSI procedure | 19.2% vs. 7.8% | 43.1% vs. 10.5% | 34.7% vs. 0% | |
(P = 0.042) | (P = 0.02) | (P = 0.003) |